Low-molecular-weight heparin for prevention of placenta-mediated pregnancy complications: protocol for a systematic review and individual patient data meta-analysis (AFFIRM)

Table 3 Potentially eligible registered trials identified by AFFIRM’s systematic review

Study name & principal investigator	Identified through	Participants	Intervention & control	Outcomes	Comment re: inclusion in IPDMA
EPPI McLintock	Ongoing RCT (New Zealand) ANZCTR registry ACTRN12609000699268	Prior PE or SGA	Enoxaparin 40 mg vs standard care	PE, SGA	Recruitment ongoing
HEPEPE Haddad	Ongoing RCT (France) Clinicaltrials.gov NCT00986765	Prior severe pre-eclampsia	Enoxaparin 4000 IU + ASA vs ASA	PE; IUGR; abruption; perinatal death	Recruitment ongoing
HOPPE Llurba	Ongoing RCT (Spain) Clinicaltrials.gov NCT01388322	Prior severe PE, SGA, loss, or abruption	Enoxaparin 40 mg or 80 mg (weight-based) vsno intervention	PE; IUGR; abruption; fetal death	Recruitment ongoing

ASA = aspirin; IPDMA = individual patient data meta-analysis; IUGR = intrauterine growth restriction; PE = pre-eclampsia; SGA = small-for-gestational age.
Trial Names:
EPPI = Enoxaparin for the Prevention of Preeclampsia and Intrauterine growth restriction.
HEPEPE = Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia (original title is French).
HOPPE = Low Weight Heparin prOphylaxis for Placental Mediated Complications of PrEgnancy.

ISSN: 2046-4053